Vortioxetine for Cognitive Impairment

"Judging by the listed criteria, this clinical trial is limited to participants between 18 and 65. For younger or older patients respectively, there are 759 and 2730 trials available for them to join."

"This clinical trial seeks 200 participants, who are between 18 and 65 years of age and experience fatigue. Moreover, the post-COVID-19 condition should be recognized by WHO's definition: 'Post COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms that last for at least 2 months...'. To guarantee eligibility criteria is met, inclusion will only occur when 12 weeks have elapsed since acute recovery from Covid 19 or if a positive antigen/PCR test result was acquired. In addition to this criterion,"

"Our team at Power gave Vortioxetine a score of 2 due to the existing safety data, though there is yet to be any evidence demonstrating its efficacy in this Phase 2 trial."

"Affirmative. According to clinicaltrials.gov, recruitment for this experiment is still underway; it was first posted on September 16th 2021 and modified as recently as July 19th 2022. 200 patients are needed at two distinct facilities."

"Firstly studied in 2016, Vortioxetine was approved for Phase 4 clinical use after the initial trial of 88 patients ran by Takeda. At present, there are 7 ongoing trials across 6 cities and countries testing out this medication."

"Affirmative. Clinicaltrials.gov reveals that the trial, initiated on September 16th 2021, is currently recruiting patients at two sites with a target of 200 participants overall."